ライフサイエンスコーパス: transitional cell carcinoma

1 inoma, adult polycystic kidney disease or in transitional cell carcinoma.

2 atment of organ-confined upper urinary tract transitional cell carcinoma.

3 line therapy and emerging drugs for advanced transitional-cell carcinoma.

4 tment has an antitumor effect in superficial transitional-cell carcinoma.

5 in patients with unresectable or metastatic transitional-cell carcinoma.

6 microsatellite loci in 20 grade III invasive transitional cell carcinomas.

7 adder proliferative lesions, including three transitional cell carcinomas.

8 ssues and normal mammary tissues and bladder transitional cell carcinomas.

9 g water and the incidence of urinary bladder transitional cell carcinomas.

10 ickening in four patients (three of whom had transitional cell carcinoma), a renal abscess, a coloves

11 In the SCID-beige mice, T24 human bladder transitional cell carcinoma also was used as the tumor i

12 he current fund of knowledge about prostatic transitional cell carcinoma and the implications for dia

13 and nature of FGFR3 mutations in a panel of transitional cell carcinomas and cell lines and studied

14 ses, 24 were renal cell carcinoma, one was a transitional cell carcinoma, and one was an angiomyolipo

15 Forty-three patients had transitional cell carcinoma, and six had squamous cell c

16 ntly it has been shown to be a human bladder transitional cell carcinoma cell line.

17 n of p27(Kip1) and cyclin E in human bladder transitional cell carcinoma cells correlates with advanc

18 sing an early-stage renal cell carcinoma and transitional cell carcinoma, chronic lymphocytic leukemi

19 PDE5 was overexpressed in human squamous and transitional cell carcinomas compared with normal urothe

20 chemotherapy in advanced upper urinary tract transitional cell carcinoma continue to evolve and remai

21 F-7, pancreatic carcinoma (CRL 1420, bladder transitional cell carcinoma EJ, and melanoma LOX) but no

22 The operative management of invasive transitional cell carcinoma has advanced significantly i

23 onsidered related to the study drug (bladder transitional cell carcinoma in the ozanezumab group and

24 Of patients with transitional-cell carcinoma (n = 776), LVI status was av

25 ancer, testis cancer and upper urinary tract transitional cell carcinoma, no recently published study

26 ase 2 trial, we enrolled patients with T2-4a transitional cell carcinoma of the bladder at 24 medical

27 Patterns of RT112 cells derived from a transitional cell carcinoma of the bladder could be depo

28 Rb) expression was evaluated in 185 cases of transitional cell carcinoma of the bladder from patients

29 Transitional cell carcinoma of the bladder is a common m

30 Transitional cell carcinoma of the bladder is comprised

31 erin and interferon are clinically active in transitional cell carcinoma of the bladder, but their me

32 s the standard treatment for muscle-invasive transitional cell carcinoma of the bladder.

33 th bacille Calmette-Guerin (BCG) -refractory transitional cell carcinoma of the bladder.

34 ir derived cell lines from two patients with transitional cell carcinoma of the bladder.

35 nti-Yo antibody response in association with transitional cell carcinoma of the bladder.

36 n a wide variety of human cancers, including transitional cell carcinoma of the bladder.

37 27(Kip1) and cyclin E, in the progression of transitional cell carcinoma of the bladder.

38 Transitional cell carcinoma of the renal pelvis or dista

39 In a patient with transitional cell carcinoma of the renal pelvis, hydrone

40 We present four cases of transitional cell carcinoma of the transplant ureter (TC

41 rectomy has been the treatment of choice for transitional cell carcinoma of the upper urinary tract.

42 lear cell) renal carcinoma (11 of 11 cases), transitional cell carcinoma of the urinary bladder (6 of

43 ssue sections of canine spontaneous invasive transitional cell carcinoma of the urinary bladder (a mo

44 s accrued from patients with muscle-invasive transitional cell carcinoma of the urinary bladder (TCC-

45 COX-1 and COX-2 expression in human invasive transitional cell carcinoma of the urinary bladder by im

46 of chromosome 3 was conducted in 72 cases of transitional cell carcinoma of the urinary bladder using

47 n pet dogs with naturally occurring invasive transitional cell carcinoma of the urinary bladder.

48 oving the precision of the estimated risk of transitional cell carcinoma of the urinary tract associa

49 ylation of four CpG islands in human urinary transitional cell carcinomas of different stages and gra

50 ed that around one-third (33/101) of primary transitional cell carcinomas of the bladder overexpress

51 More than 50% of transitional cell carcinomas of the bladder show loss of

52 ation of these genes by analyzing 69 primary transitional cell carcinomas of the bladder with a panel

53 but was detected in 25 of 29 (86%) invasive transitional cell carcinomas of the urinary bladder and

54 ity, we have studied a cohort of superficial transitional cell carcinomas of the urinary bladder by i

55 ed the pattern of allelic imbalance in human transitional cell carcinomas of the urinary bladder incl

56 ymphadenectomy, with the intent to cure, for transitional-cell carcinoma of the bladder between July

57 Patients with measurable, locally advanced transitional-cell carcinoma of the bladder who were not

58 STT1, GSTM3, and GSTP1 in 1150 patients with transitional-cell carcinoma of the urinary bladder and 1

59 al urotoxicity, including the development of transitional-cell carcinoma of the urinary bladder.

60 Seven patients (5%) developed transitional-cell carcinoma of the urinary bladder.

61 ond-line treatment of patients with advanced transitional-cell carcinoma of the urothelial tract.

62 overall survival for patients with advanced transitional-cell carcinoma of the urothelium.

63 n of the bladder tumor and biopsy identified transitional cell carcinoma or urothelial carcinoma inva

64 sic fibroblast growth factor (bFGF) in human transitional cell carcinoma, reduce its angiogenesis, an

65 Transitional cell carcinoma should be considered in pati

66 Bladder cancer cell lines (J82, T24 and transitional cell carcinoma) significantly restored hepa

67 identified as a region of non-random LOH in transitional cell carcinoma, suggesting the presence of

68 y included 59 well-characterized superficial transitional cell carcinomas (Ta, n = 28; T1, n = 31) fo

69 Treatment of T24 and transitional cell carcinoma TCC-SUP bladder cancer cells

70 onstrated absent or greatly reduced pinin in transitional cell carcinoma (TCC) and RCC tumors.

71 y culture (P0) and after passage in vitro of transitional cell carcinoma (TCC) biopsies that represen

72 ghly tumorigenic and highly metastatic human transitional cell carcinoma (TCC) cell line 253J B-V ove

73 ltetrazolium bromide (MTT) assays in bladder transitional cell carcinoma (TCC) cell lines RT4 and SW7

74 and protein are observed among several human transitional cell carcinoma (TCC) cell lines, suggesting

75 GF) accumulates in the nucleus in aggressive transitional cell carcinoma (TCC) cells and this histolo

76 Human transitional cell carcinoma (TCC) cells are labeled with

77 ptor (BMP-R) types IA, IB, and II in bladder transitional cell carcinoma (TCC) cells.

78 IFN-alpha therapy for clinical treatment of transitional cell carcinoma (TCC) has prompted us to inv

79 Transitional cell carcinoma (TCC) is a pan-urothelial di

80 therapy surgery for patients with metastatic transitional cell carcinoma (TCC) is controversial.

81 Prostatic transitional cell carcinoma (TCC) is present in up to 48

82 of noninvasive methods for the diagnosis of transitional cell carcinoma (TCC) of the bladder remains

83 We have screened 193 cases of transitional cell carcinoma (TCC) of the bladder using 3

84 invasive method for monitoring patients with transitional cell carcinoma (TCC) of the bladder would b

85 q is the most frequent genetic alteration in transitional cell carcinoma (TCC) of the bladder, implic

86 ured biopsies of superficial and myoinvasive transitional cell carcinoma (TCC) of the bladder.

87 vement in the development and progression of transitional cell carcinoma (TCC) of the bladder.

88 9 are the most common genetic alteration in transitional cell carcinoma (TCC) of the bladder.

89 e identify a potential role for proHB-EGF in transitional cell carcinoma (TCC) of the bladder.

90 mine the relative levels of MSI and EMAST in transitional cell carcinoma (TCC) of the upper and lower

91 eleted in many human malignancies, including transitional cell carcinoma (TCC) of the urinary bladder

92 ations are known to be associated with human transitional cell carcinoma (TCC) of the urinary bladder

93 Our microRNA profiling of bladder transitional cell carcinoma (TCC) patient samples reveal

94 orifice positive for a high-grade papillary transitional cell carcinoma (TCC) with muscularis propri

95 on forms of bladder tumors: 69 of 97 (71.1%) transitional cell carcinoma (TCC), 38 of 53 (71.6%) squa

96 Transitional cell carcinoma (TCC), a neoplasm of urinary

97 remains the standard of care for metastatic transitional cell carcinoma (TCC), but its limitations i

98 predominant component in the development of transitional cell carcinoma (TCC), but the particular pa

99 Transitional cell carcinoma (TCC), the most common cance

100 be well tolerated in patients with advanced transitional cell carcinoma (TCC).

101 proven modality for treatment of upper-tract transitional cell carcinoma (TCC).

102 potential as an immunotherapeutic target in transitional cell carcinoma (TCC).

103 dies demonstrated chromosome 3p deletions in transitional cell carcinoma (TCC).

104 invasive or high-grade recurrent superficial transitional cell carcinoma (TCC; lymph node-negative, 1

105 pure squamous cell carcinomas (SCC), and in transitional cell carcinomas (TCC) of the bladder with S

106 five sarcomatoid RCC, two oncocytomas, three transitional cell carcinomas (TCC) of the renal pelvis a

107 FGFR3 coding sequence from 63 transitional cell carcinomas (TCC) of various stages and

108 elial carcinomas, including 28 pTa low-grade transitional cell carcinomas (TCC), 31 pTa high-grade TC

109 d primarily patients with non-organ-confined transitional-cell carcinoma (TCC) of the bladder.

110 ed as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the bladder.

111 nd carboplatin for the treatment of advanced transitional-cell carcinoma (TCC) of the urothelium has

112 in previously treated patients with advanced transitional-cell carcinoma (TCC) of the urothelium.

113 previously untreated patients with advanced transitional-cell carcinoma (TCC) to assess its efficacy

114 eported survival of patients with metastatic transitional-cell carcinoma (TCC) treated with systemic

115 icacy and toxicity in patients with advanced transitional-cell carcinoma (TCC) who had failed to resp

116 b and p53 pathway alterations in 12 invasive transitional cell carcinomas (TCCs) and addressed the fu

117 A survey of 50 transitional cell carcinomas (TCCs) revealed a UP-II pol

118 In transitional cell carcinoma, the most common form of bla

119 Using a murine transitional cell carcinoma tumor model, MB49, which nat

120 We measured DNA methylation in 342 transitional cell carcinoma tumors at BCL2, PTGS2 (COX2)

121 Additionally, transitional cell carcinoma was observed in approximatel

122 % of the K5.COX-2 transgenic mice; no TCH or transitional cell carcinoma was observed in wild-type bl

123 of 31 consecutive patients with renal pelvic transitional cell carcinoma were evaluated.

124 NU plus H202 or H202 alone formed high-grade transitional cell carcinomas when injected into nude mic

125 st described in 1991 for upper urinary tract transitional cell carcinoma, with long-term data now eme